Supported by

TAVI (Transcatheter aortic valve implantation)

Find all the latest content on TAVI published on this website.

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Use the filters below to access PCRonline resources.

Anatomy of the aortic valvar complex

View a detailed and comprehensive description of the anatomy of the aortic valvar complex as it pertains to TAVI.

View illustrated aortic valvar complex

Filtered By
TAVI

1632 results

TAVI in challenging annular anatomy

17 Nov 2025 – From PCR London Valves 2025

This session addresses the complexities of performing TAVI in challenging annular anatomies. It features case studies such as TAVI-in-TAVI in a patient with Morquio syndrome, strategies for managing severe annular calcification including calcium cracking techniques, and the use of large-diameter Myval valves for very large annuli...

TAVI in challenging scenarios

17 Nov 2025 – From PCR London Valves 2025

This session explores complex and emergent scenarios in TAVI, featuring cases such as emergent transfemoral TAVI in failing homograft roots complicated by extensive aortic dissection, the use of BASILICA in high-risk left main occlusion terrain, and the aorto-mitral challenges during TAVR. It also covers innovative coronary...

TAVI in patients with concomitant valve and coronary artery disease

17 Nov 2025 – From PCR London Valves 2025

Focused on patients with concomitant valve and coronary artery disease, this session examines evaluation strategies for aortic stenosis burden, integrates recent trial data on combined TAVI and PCI, and discusses optimal management approaches in complex multi-valve disease scenarios through detailed case presentations and clinical outcomes.

TAVI in patients with concomitant valve and coronary artery disease

TAVI Valve-in-Valve: Managing unexpected anatomical challenges

17 Nov 2025 – From PCR London Valves 2025

This session examines valve-in-valve interventions in TAVI, highlighting management of concomitant left main disease, unique case narratives such as "The Highlander story," and the unpredictability inherent in these procedures. It also reviews successful transfemoral TAV-in-SAV interventions in acute heparin-induced thrombocytopenia and addresses treatment of degenerated sutureless...

TAVI Valve-in-Valve: Managing unexpected anatomical challenges

TAVI for pure aortic regurgitation: different animal, different challenges, different approaches

17 Nov 2025 – From PCR London Valves 2025

This session delves into the unique anatomical and pathophysiological challenges posed by pure aortic regurgitation and their impact on treatment strategies. It reviews clinical outcomes with established and new transcatheter devices, and presents emerging technologies that promise to advance therapeutic options for this distinct patient population.

TAVI for pure aortic regurgitation: different animal, different challenges, different approaches

TAVI valve-in-valve - Paravalvular leak management & complex anatomies

17 Nov 2025 – From PCR London Valves 2025

This session explores the complexities of valve-in-valve TAVI procedures, with a focus on managing paravalvular leaks in failed bioprosthetic valves. It covers challenging cases where surgery is not an option, intricate anatomical considerations, differential diagnosis of paravalvular leaks, and strategies for redo TAVI interventions to optimize...

TAVI valve-in-valve - Paravalvular leak management & complex anatomies

TAVI: complex vascular access

17 Nov 2025 – From PCR London Valves 2025

This session addresses the challenges of complex vascular access in transcatheter aortic valve implantation (TAVI). It discusses strategies for navigating difficult thoraco-abdominal aortic anatomies, managing double aortic arches, and overcoming hostile femoral access. Case studies illustrate meticulous planning and innovative solutions essential for successful TAVI in...

TAVI: nightmare in the cathlab - Annular perforation, coronary obstruction & balloon rupture

17 Nov 2025 – From PCR London Valves 2025

This session presents critical case analyses of complicated TAVI procedures, highlighting unexpected and severe intra-procedural events such as annular perforation, leaflet modification complications, coronary obstructions, and device failures. It emphasizes prevention strategies, bailout techniques, and acute management to prepare clinicians for handling TAVI-related emergencies effectively.

TAVI: nightmare in the cathlab - Annular perforation, coronary obstruction & balloon rupture

Exceptional engineering, predictable outcomes - Latest development of the VitaFlow TAVI device

17 Nov 2025 – From PCR London Valves 2025

Discover the latest advancements in the VitaFlow transcatheter aortic valve implantation (TAVI) device. This session highlights the electronically enabled VitaFlow Liberty system, delivering consistent immediate and mid-term clinical results. Watch real-world demonstrations of complex cases, including heavily calcified aortas and pure aortic regurgitation, and get a...

Exceptional engineering, predictable outcomes - Latest development of the VitaFlow TAVI device

Prevention and management of TAVI complications

17 Nov 2025 – From PCR London Valves 2025

This session is dedicated to the prevention and management of complications associated with transcatheter aortic valve implantation (TAVI). Participants gain critical knowledge on managing vascular access challenges, anticipating and preventing valve malposition, handling device embolism, and evaluating coronary obstruction risks with effective prevention and bailout strategies.

Prevention and management of TAVI complications

How to manage patients with aortic stenosis and coronary artery disease?

17 Nov 2025 – From PCR London Valves 2025

Tiffany Patterson and Davide Capodanno address the increasingly common scenario of managing coronary artery disease (CAD) in patients undergoing TAVI. With up to half of TAVI candidates presenting with CAD, they highlight new evidence from NOTION-3 showing that revascularization reduces major adverse cardiac events. The takeaway:...

How to manage patients with aortic stenosis and coronary artery disease?

Why is TAVI a different procedure in patient with pure aortic regurgitation?

17 Nov 2025 – From PCR London Valves 2025

In this video, Juan Granada, Michael Borger and Joao Cavalcante highlight that aortic insufficiency differs from aortic stenosis and is often underestimated. Early, comprehensive evaluation and imaging are crucial. Surgery is standard for severe cases, while TAVI with dedicated devices is an option for high-risk patients.

This...

Why is TAVI a different procedure in patient with pure aortic regurgitation?

The D-PACE scoring system Prediction of high-grade conduction disturbances after TAVI

16 Nov 2025 – From PCR London Valves 2025

Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after TAVI—an unmet clinical need given that current risk models focus mainly on early events. The next steps aim to refine the...

The D-PACE scoring system - Can we predict high-grade conduction disturbances after TAVI?

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

16 Nov 2025 – From PCR London Valves 2025

Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.

They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

Is iatrogenic atrial septum defect closure a necessary procedure?

17 Nov 2025 – From PCR London Valves 2025

Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure...

Is iatrogenic atrial septum defect closure a necessary procedure?

How do we meet the needs of women with heart valve disease?

17 Nov 2025 – From PCR London Valves 2025

In this interview, Ellen Ross and Marta Sitges discuss a recent initiative from Global Heart Hub - a patient association - which examined the realities faced by women living with heart valve disease. They outline the gaps identified, the call to action that followed, and how...

How do we meet the needs of women with heart valve disease?

How to manage current challenges of small aortic annulus?

18 Nov 2025 – From PCR London Valves 2025

Joanna Wykrzykowska and Hélène Eltchaninoff discuss challenges in treating patients with small aortic annuli, which are common, especially in women, and present risks such as higher gradients, coronary occlusion, pacemaker need, and paravalvular leak. Valve selection and positioning are critical, balancing hemodynamics and complication avoidance.

This interview...

How to manage current challenges of small aortic annulus?

Aortic valve: PCR London Valves 2025 highlights

17 Nov 2025 – From PCR London Valves 2025

At PCR London Valves 2025, Chris Cook speaks with Course Directors Bernard Prendergast and Simon Redwood about the main highlights from the aortic track. They underline the growing focus on lifetime management, including valve choice, future coronary access, durability, and new long-term data supporting TAVI in...

PCR London Valves 2025 highlights: Focus on aortic valve

From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS

16 Nov 2025 – From PCR London Valves 2025

Francesco Saia discusses the clinical benefits of early intervention in asymptomatic severe aortic stenosis with Philippe Généreux and Tiffany Patterson. EARLY TAVR trial and supporting studies showed a reduction in death, stroke, and heart failure compared with surveillance. Economic modelling shows early intervention is cost-effective and...

From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS

Getting the full potential of the supra-annular valve in a changing landscape

16 Nov 2025 – From PCR London Valves 2025

This session explores the evolving landscape of transcatheter aortic valve implantation (TAVI) with a focus on supra-annular valve technology. It covers techniques for achieving commissural alignment, considerations for small aortic annuli, and advantages in treating bicuspid aortic valve disease, supported by clinical data and illustrative cases.

Getting the full potential of the supra-annular valve in a changing landscape